3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Melanoma
1
Interventions
Petrolatum
2
Fluorouracil
2
trametinib
1
talimogene laherparepvec
1
sargramostim
1
reolysin
1
pimonidazole
1
pembrolizumab
1
fluoromisonidazole
1
dabrafenib
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Surgical Procedures, Operative
1
Sugars
1
Radiotherapy
1
Radiation
1
Povidone-Iodine
1
Melphalan
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Erlotinib Hydrochloride
1
Clindamycin
1
Clarithromycin
1
Cephalexin
1
Azithromycin
1
Anti-Bacterial Agents
1
Amoxicillin
1
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Skin Neoplasms
×
reolysin
×
Clear all
NCT03282188
2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2
Withdrawn